Melinda Irwin, PhD, MPH is the Susan Dwight Bliss Professor of Epidemiology and Associate Dean of Research at the Yale School of Public Health, Deputy Director of the Yale Cancer Center, and Deputy Director (Public Health) in the Yale Center for Clinical Investigation. Her academic appointments include Professor of Chronic Disease Epidemiology at Yale School of Public Health, membership in the Cancer Prevention and Control Program, the Diabetes Research Center, and leadership of the Irwin Lab (LEAN Study). She also participates in the Obesity Research Working Group and the Transdisciplinary Research in Energetics and Cancer Research Education Program. Dr. Irwin is a prominent leader in cancer prevention and survivorship research with over 20 years of experience. Her work focuses on randomized trials examining how exercise and weight loss interventions affect biological markers, treatment side effects, and quality of life in cancer patients. She has received funding from the National Institutes of Health, American Cancer Society, Breast Cancer Research Foundation, American Institute for Cancer Research, Komen for the Cure, and Livestrong Foundation. Her research spans breast cancer, ovarian cancer, and lung cancer survivorship, with particular emphasis on how lifestyle factors influence treatment outcomes and long-term survivorship. Dr. Irwin's recent publications show a strong focus on lifestyle interventions during active cancer treatment, examining how weight management and physical activity impact chemotherapy completion rates, endocrine therapy adherence, and overall quality of life. Her work increasingly addresses health disparities, with studies examining barriers to lifestyle changes among underserved populations including Black and Latina women. She has made significant contributions to understanding the relationship between obesity, exercise, and cancer outcomes across multiple disease sites. Dr. Irwin has advised, mentored and trained over 100 trainees at Yale and leads two major training programs: an NCI T32-funded Cancer Prevention and Control Training Program and an NCI R25-funded Transdisciplinary Research on Energetics and Cancer Training Program. Her leadership extends beyond Yale as she co-leads the SWOG Cancer Research Network Cancer Survivorship Committee. In 2018, she completed the Hedwig van Ameringen Executive Leadership in Academic Medicine (ELAM) Program, demonstrating her commitment to leadership development in academic medicine.





